Stock IBP INDO-BANGLA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Indo-Bangla Pharmaceuticals Limited

Equities

IBP

BD0494IBPL08

Pharmaceuticals

End-of-day quote Dhaka S.E.
Other stock markets
 18:00:00 2024-05-29 EDT 		5-day change 1st Jan Change
13.5 BDT +1.50% Intraday chart for Indo-Bangla Pharmaceuticals Limited -1.46% -28.57%
05-13 Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
02-11 Indo-Bangla Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023
Capitalization 1 2,404 2,230 2,186 2,036 1,975
Enterprise Value (EV) 1 2,243 2,216 2,249 2,078 2,008
P/E ratio 13.7 x 14.3 x 16.2 x 82.6 x 235 x
Yield 0.93% - 2.08% 0.56% -
Capitalization / Revenue 3.24 x 2.57 x 2.8 x 4.2 x 5.28 x
EV / Revenue 3.03 x 2.56 x 2.87 x 4.29 x 5.36 x
EV / EBITDA 11.7 x 9.21 x 10.7 x 27.7 x 29.9 x
EV / FCF -14.1 x -14.1 x -25.6 x 25.9 x 128 x
FCF Yield -7.08% -7.09% -3.9% 3.85% 0.78%
Price to Book 1.75 x 1.47 x 1.35 x 1.28 x 1.22 x
Nbr of stocks (in thousands) 113,737 113,737 113,737 113,737 116,205
Reference price 2 21.13 19.61 19.22 17.90 17.00
Announcement Date 19-11-27 21-12-06 21-12-06 22-12-13 23-11-22
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net sales 1 660 740.7 866.1 782.2 484.7 374.5
EBITDA 1 162.7 191.2 240.7 209.2 74.93 67.05
EBIT 1 145.6 169.2 211.8 173.3 35.8 28.68
Operating Margin 22.06% 22.85% 24.46% 22.15% 7.39% 7.66%
Earnings before Tax (EBT) 1 151.5 180.8 217 169.3 31.72 24.57
Net income 1 98.49 155.2 156.2 134.7 25.17 8.407
Net margin 14.92% 20.96% 18.04% 17.22% 5.19% 2.24%
EPS 2 1.103 1.547 1.374 1.185 0.2166 0.0723
Free Cash Flow 1 -39.71 -158.9 -157.1 -87.68 80.07 15.65
FCF margin -6.02% -21.45% -18.14% -11.21% 16.52% 4.18%
FCF Conversion (EBITDA) - - - - 106.86% 23.34%
FCF Conversion (Net income) - - - - 318.06% 186.11%
Dividend per Share - 0.1961 - 0.4000 0.1000 -
Announcement Date 18-10-25 19-11-27 21-12-06 21-12-06 22-12-13 23-11-22
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 62.5 41.7 32.3
Net Cash position 1 91.7 161 13.8 - - -
Leverage (Debt/EBITDA) - - - 0.2986 x 0.5561 x 0.4819 x
Free Cash Flow 1 -39.7 -159 -157 -87.7 80.1 15.6
ROE (net income / shareholders' equity) 9.98% 12.9% 10.8% 8.57% 1.55% 0.52%
ROA (Net income/ Total Assets) 7.92% 7.54% 7.96% 5.97% 1.18% 0.95%
Assets 1 1,243 2,059 1,962 2,258 2,137 883.9
Book Value Per Share 2 11.60 12.10 13.40 14.30 14.00 14.00
Cash Flow per Share 2 1.030 1.410 0.1200 0.2000 0.2900 0.1000
Capex 1 113 182 309 200 39.7 30
Capex / Sales 17.06% 24.57% 35.68% 25.62% 8.19% 8.02%
Announcement Date 18-10-25 19-11-27 21-12-06 21-12-06 22-12-13 23-11-22
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
INDO-BANGLA PHARMACEUTICALS LIMITED Stock Indo-Bangla Pharmaceuticals Limited
-28.57% 13.36M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IBP Stock
  4. Financials Indo-Bangla Pharmaceuticals Limited